Rajeev Vibhakar
Concepts (414)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medulloblastoma | 40 | 2025 | 215 | 10.450 |
Why?
| | Cerebellar Neoplasms | 30 | 2025 | 177 | 8.470 |
Why?
| | Rhabdoid Tumor | 11 | 2025 | 103 | 3.590 |
Why?
| | Gene Expression Regulation, Neoplastic | 30 | 2025 | 1455 | 3.540 |
Why?
| | Glioma | 19 | 2025 | 425 | 3.530 |
Why?
| | Brain Neoplasms | 27 | 2025 | 1318 | 3.310 |
Why?
| | Radiation Tolerance | 8 | 2025 | 103 | 2.540 |
Why?
| | Proto-Oncogene Proteins c-myc | 8 | 2025 | 167 | 2.510 |
Why?
| | Cell Cycle Proteins | 8 | 2022 | 628 | 2.080 |
Why?
| | Cell Line, Tumor | 38 | 2025 | 3539 | 1.900 |
Why?
| | Cell Proliferation | 27 | 2025 | 2494 | 1.660 |
Why?
| | Teratoma | 6 | 2025 | 120 | 1.660 |
Why?
| | SMARCB1 Protein | 4 | 2025 | 34 | 1.550 |
Why?
| | Ependymoma | 11 | 2025 | 176 | 1.400 |
Why?
| | Protein-Tyrosine Kinases | 4 | 2020 | 433 | 1.310 |
Why?
| | Nuclear Proteins | 10 | 2025 | 748 | 1.220 |
Why?
| | Apoptosis | 20 | 2025 | 2430 | 1.100 |
Why?
| | Biomarkers, Tumor | 10 | 2025 | 1313 | 1.080 |
Why?
| | Proto-Oncogene Proteins | 4 | 2022 | 623 | 1.060 |
Why?
| | Pyrazoles | 7 | 2022 | 509 | 1.060 |
Why?
| | Neoplastic Stem Cells | 6 | 2025 | 412 | 1.000 |
Why?
| | Epigenesis, Genetic | 5 | 2025 | 684 | 0.970 |
Why?
| | Cyclin-Dependent Kinase 8 | 1 | 2025 | 50 | 0.910 |
Why?
| | Molecular Targeted Therapy | 4 | 2021 | 431 | 0.890 |
Why?
| | Brain Stem Neoplasms | 4 | 2021 | 87 | 0.890 |
Why?
| | Sirtuin 2 | 1 | 2025 | 27 | 0.890 |
Why?
| | Cyclin-Dependent Kinase 6 | 4 | 2020 | 49 | 0.880 |
Why?
| | Pyrimidines | 8 | 2019 | 532 | 0.880 |
Why?
| | Antineoplastic Agents | 10 | 2022 | 2192 | 0.850 |
Why?
| | Radiation-Sensitizing Agents | 2 | 2016 | 43 | 0.840 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2025 | 881 | 0.810 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2019 | 339 | 0.800 |
Why?
| | Genes, myc | 3 | 2020 | 50 | 0.770 |
Why?
| | Xenograft Model Antitumor Assays | 10 | 2025 | 928 | 0.770 |
Why?
| | MicroRNAs | 5 | 2020 | 700 | 0.770 |
Why?
| | Protein Biosynthesis | 1 | 2025 | 458 | 0.750 |
Why?
| | Hedgehog Proteins | 7 | 2022 | 197 | 0.750 |
Why?
| | Pyrimidinones | 4 | 2020 | 126 | 0.750 |
Why?
| | Cell Cycle | 12 | 2025 | 596 | 0.740 |
Why?
| | Cellular Senescence | 3 | 2019 | 226 | 0.710 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 66 | 0.700 |
Why?
| | Glioblastoma | 4 | 2025 | 353 | 0.690 |
Why?
| | Receptor, trkC | 1 | 2021 | 10 | 0.680 |
Why?
| | Infratentorial Neoplasms | 4 | 2025 | 71 | 0.670 |
Why?
| | Receptor, trkB | 1 | 2021 | 36 | 0.670 |
Why?
| | Mice | 26 | 2025 | 18329 | 0.660 |
Why?
| | Anilides | 3 | 2019 | 84 | 0.660 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 1 | 2021 | 64 | 0.640 |
Why?
| | Humans | 96 | 2025 | 144261 | 0.640 |
Why?
| | Chromatin | 6 | 2025 | 561 | 0.640 |
Why?
| | Gene Expression Profiling | 15 | 2024 | 1782 | 0.630 |
Why?
| | Transcriptional Elongation Factors | 1 | 2020 | 39 | 0.620 |
Why?
| | Central Nervous System Neoplasms | 4 | 2019 | 173 | 0.620 |
Why?
| | DNA Repair | 2 | 2024 | 255 | 0.610 |
Why?
| | Tumor Cells, Cultured | 10 | 2025 | 919 | 0.610 |
Why?
| | Pteridines | 2 | 2016 | 22 | 0.580 |
Why?
| | Deoxycytidine | 1 | 2020 | 221 | 0.570 |
Why?
| | Cerebellum | 5 | 2022 | 223 | 0.560 |
Why?
| | Membrane Glycoproteins | 1 | 2021 | 496 | 0.550 |
Why?
| | Oligonucleotide Array Sequence Analysis | 10 | 2016 | 758 | 0.550 |
Why?
| | Transcription Factors | 6 | 2023 | 1739 | 0.540 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 529 | 0.540 |
Why?
| | Cell Differentiation | 8 | 2025 | 2048 | 0.540 |
Why?
| | Histones | 4 | 2020 | 668 | 0.520 |
Why?
| | Animals | 28 | 2025 | 38030 | 0.510 |
Why?
| | Blotting, Western | 8 | 2019 | 1187 | 0.500 |
Why?
| | Vinblastine | 1 | 2016 | 75 | 0.500 |
Why?
| | RNA, Small Interfering | 4 | 2022 | 634 | 0.490 |
Why?
| | Checkpoint Kinase 1 | 1 | 2016 | 27 | 0.490 |
Why?
| | Mutation | 9 | 2025 | 4085 | 0.490 |
Why?
| | Bilirubin | 1 | 2016 | 97 | 0.480 |
Why?
| | Transcriptome | 7 | 2025 | 1044 | 0.480 |
Why?
| | Radiation, Ionizing | 3 | 2022 | 87 | 0.480 |
Why?
| | Cell Survival | 8 | 2019 | 1098 | 0.480 |
Why?
| | Vincristine | 1 | 2016 | 140 | 0.470 |
Why?
| | CRISPR-Cas Systems | 3 | 2025 | 170 | 0.460 |
Why?
| | Enzyme Inhibitors | 6 | 2020 | 824 | 0.450 |
Why?
| | Child | 32 | 2025 | 22537 | 0.450 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2016 | 139 | 0.440 |
Why?
| | Polycomb Repressive Complex 2 | 2 | 2012 | 81 | 0.430 |
Why?
| | Proto-Oncogene Proteins B-raf | 3 | 2025 | 225 | 0.430 |
Why?
| | Histone Deacetylase Inhibitors | 3 | 2023 | 220 | 0.410 |
Why?
| | Single-Cell Analysis | 5 | 2025 | 356 | 0.410 |
Why?
| | RNA, Messenger | 7 | 2014 | 2829 | 0.390 |
Why?
| | Repressor Proteins | 3 | 2022 | 437 | 0.360 |
Why?
| | Child, Preschool | 19 | 2025 | 11774 | 0.340 |
Why?
| | Piperazines | 3 | 2022 | 380 | 0.330 |
Why?
| | Tumor Microenvironment | 3 | 2025 | 732 | 0.320 |
Why?
| | Transcription, Genetic | 3 | 2025 | 1495 | 0.320 |
Why?
| | Azepines | 3 | 2019 | 107 | 0.320 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 6 | 2014 | 981 | 0.320 |
Why?
| | Prognosis | 9 | 2020 | 4278 | 0.320 |
Why?
| | Neoplasms, Neuroepithelial | 2 | 2020 | 14 | 0.320 |
Why?
| | NF-kappa B | 5 | 2025 | 661 | 0.310 |
Why?
| | Intracellular Space | 1 | 2010 | 66 | 0.310 |
Why?
| | Genes, Tumor Suppressor | 2 | 2007 | 82 | 0.310 |
Why?
| | Neoplasm Proteins | 2 | 2012 | 442 | 0.310 |
Why?
| | Reactive Oxygen Species | 2 | 2022 | 621 | 0.290 |
Why?
| | Cisplatin | 3 | 2016 | 334 | 0.290 |
Why?
| | Real-Time Polymerase Chain Reaction | 4 | 2014 | 341 | 0.290 |
Why?
| | Drug Screening Assays, Antitumor | 4 | 2021 | 191 | 0.280 |
Why?
| | Chromosomes, Human, Pair 1 | 2 | 2019 | 78 | 0.280 |
Why?
| | Quinazolines | 2 | 2022 | 266 | 0.270 |
Why?
| | Protein Kinase Inhibitors | 2 | 2014 | 968 | 0.270 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 1953 | 0.270 |
Why?
| | Signal Transduction | 10 | 2025 | 5221 | 0.260 |
Why?
| | Mice, Nude | 3 | 2020 | 682 | 0.250 |
Why?
| | Aurora Kinases | 3 | 2012 | 28 | 0.250 |
Why?
| | B7 Antigens | 2 | 2020 | 18 | 0.250 |
Why?
| | DNA-Binding Proteins | 3 | 2017 | 1497 | 0.250 |
Why?
| | Aurora Kinase A | 3 | 2012 | 62 | 0.250 |
Why?
| | Combined Modality Therapy | 6 | 2019 | 1264 | 0.250 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2025 | 549 | 0.250 |
Why?
| | Phagocytosis | 2 | 2025 | 299 | 0.240 |
Why?
| | Female | 28 | 2025 | 77976 | 0.240 |
Why?
| | AC133 Antigen | 1 | 2025 | 20 | 0.230 |
Why?
| | Polycomb Repressive Complex 1 | 2 | 2020 | 66 | 0.230 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 3 | 2023 | 56 | 0.230 |
Why?
| | Autophagy | 2 | 2019 | 285 | 0.230 |
Why?
| | 12E7 Antigen | 1 | 2025 | 10 | 0.230 |
Why?
| | Epigenomics | 3 | 2020 | 114 | 0.230 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2025 | 70 | 0.230 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2007 | 381 | 0.220 |
Why?
| | Triazoles | 2 | 2019 | 184 | 0.220 |
Why?
| | Ganglioglioma | 1 | 2025 | 34 | 0.220 |
Why?
| | RNA Polymerase II | 2 | 2025 | 350 | 0.220 |
Why?
| | Gene Fusion | 1 | 2025 | 29 | 0.220 |
Why?
| | SOXB1 Transcription Factors | 1 | 2025 | 67 | 0.220 |
Why?
| | Bone Morphogenetic Proteins | 2 | 2019 | 142 | 0.220 |
Why?
| | Protein-Arginine N-Methyltransferases | 1 | 2025 | 25 | 0.220 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2022 | 1137 | 0.220 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2005 | 103 | 0.210 |
Why?
| | Phenanthrenes | 1 | 2024 | 12 | 0.210 |
Why?
| | Diterpenes | 1 | 2024 | 26 | 0.210 |
Why?
| | Epoxy Compounds | 1 | 2024 | 32 | 0.210 |
Why?
| | Positive Transcriptional Elongation Factor B | 1 | 2024 | 29 | 0.210 |
Why?
| | Macrophage Activation | 1 | 2025 | 193 | 0.210 |
Why?
| | Gene Rearrangement | 1 | 2025 | 155 | 0.210 |
Why?
| | Abnormalities, Multiple | 1 | 2005 | 197 | 0.200 |
Why?
| | Survival Rate | 5 | 2020 | 2088 | 0.200 |
Why?
| | Benzamides | 4 | 2023 | 224 | 0.190 |
Why?
| | Metencephalon | 1 | 2022 | 1 | 0.190 |
Why?
| | Cell Lineage | 2 | 2022 | 376 | 0.190 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2025 | 449 | 0.180 |
Why?
| | Disease-Free Survival | 3 | 2016 | 768 | 0.180 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2022 | 44 | 0.180 |
Why?
| | Stress, Physiological | 1 | 2025 | 453 | 0.180 |
Why?
| | von Willebrand Diseases | 1 | 2022 | 28 | 0.180 |
Why?
| | DNA Copy Number Variations | 4 | 2021 | 183 | 0.180 |
Why?
| | Genome, Human | 3 | 2014 | 422 | 0.180 |
Why?
| | Spheroids, Cellular | 2 | 2012 | 73 | 0.180 |
Why?
| | von Willebrand Factor | 1 | 2022 | 85 | 0.170 |
Why?
| | Radiation | 1 | 2021 | 24 | 0.170 |
Why?
| | Neural Stem Cells | 2 | 2012 | 166 | 0.160 |
Why?
| | Mice, Transgenic | 3 | 2021 | 2182 | 0.160 |
Why?
| | RNA, Long Noncoding | 2 | 2021 | 177 | 0.160 |
Why?
| | Pyridines | 3 | 2019 | 605 | 0.160 |
Why?
| | Fatal Outcome | 1 | 2021 | 307 | 0.160 |
Why?
| | Receptor, EphB4 | 1 | 2020 | 33 | 0.160 |
Why?
| | Macrophages | 2 | 2025 | 1510 | 0.160 |
Why?
| | Ephrin-B2 | 1 | 2020 | 45 | 0.160 |
Why?
| | Antigens, Surface | 2 | 1997 | 157 | 0.160 |
Why?
| | Colony-Forming Units Assay | 2 | 2012 | 95 | 0.160 |
Why?
| | Craniospinal Irradiation | 1 | 2019 | 5 | 0.160 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2020 | 81 | 0.150 |
Why?
| | Receptors, Nerve Growth Factor | 1 | 2019 | 18 | 0.150 |
Why?
| | RNA, Small Nuclear | 1 | 2019 | 38 | 0.150 |
Why?
| | Adolescent | 13 | 2025 | 22281 | 0.150 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2017 | 2026 | 0.150 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2019 | 210 | 0.150 |
Why?
| | Karyopherins | 1 | 2019 | 20 | 0.150 |
Why?
| | Kaplan-Meier Estimate | 3 | 2017 | 964 | 0.150 |
Why?
| | Proteins | 3 | 2021 | 1021 | 0.140 |
Why?
| | Phenotype | 3 | 2024 | 3157 | 0.140 |
Why?
| | Cell Self Renewal | 1 | 2019 | 53 | 0.140 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2021 | 905 | 0.140 |
Why?
| | Base Sequence | 4 | 2012 | 2187 | 0.140 |
Why?
| | Male | 21 | 2025 | 72035 | 0.140 |
Why?
| | Infant | 12 | 2021 | 10022 | 0.140 |
Why?
| | Chemoradiotherapy | 1 | 2019 | 237 | 0.140 |
Why?
| | Antibodies, Monoclonal | 1 | 2025 | 1519 | 0.140 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2019 | 209 | 0.130 |
Why?
| | Genes, p16 | 1 | 2017 | 13 | 0.130 |
Why?
| | Neoplasms | 2 | 2025 | 2870 | 0.130 |
Why?
| | Everolimus | 1 | 2017 | 111 | 0.130 |
Why?
| | E2F Transcription Factors | 1 | 2017 | 62 | 0.130 |
Why?
| | Sulfonamides | 2 | 2022 | 580 | 0.130 |
Why?
| | Recombinational DNA Repair | 1 | 2017 | 19 | 0.130 |
Why?
| | Cohort Studies | 6 | 2021 | 5935 | 0.130 |
Why?
| | Morpholines | 1 | 2017 | 128 | 0.130 |
Why?
| | Cell Division | 2 | 2010 | 766 | 0.130 |
Why?
| | DNA Methylation | 4 | 2021 | 681 | 0.130 |
Why?
| | DNA Damage | 2 | 2017 | 428 | 0.130 |
Why?
| | Chloroquine | 1 | 2017 | 53 | 0.130 |
Why?
| | Phthalazines | 1 | 2017 | 64 | 0.120 |
Why?
| | Benzodiazepinones | 1 | 2016 | 18 | 0.120 |
Why?
| | Up-Regulation | 2 | 2016 | 851 | 0.120 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2016 | 24 | 0.120 |
Why?
| | Electric Stimulation Therapy | 1 | 2017 | 62 | 0.120 |
Why?
| | Stem Cells | 1 | 2021 | 625 | 0.120 |
Why?
| | Chromosome Aberrations | 1 | 2017 | 162 | 0.120 |
Why?
| | Microarray Analysis | 2 | 2017 | 117 | 0.120 |
Why?
| | Immunophenotyping | 1 | 2017 | 322 | 0.120 |
Why?
| | Urea | 1 | 2016 | 84 | 0.120 |
Why?
| | Neoplasm Invasiveness | 2 | 2020 | 508 | 0.120 |
Why?
| | Thiophenes | 1 | 2016 | 128 | 0.120 |
Why?
| | In Situ Hybridization, Fluorescence | 3 | 2025 | 322 | 0.110 |
Why?
| | Lysine | 2 | 2020 | 302 | 0.110 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2016 | 177 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2017 | 436 | 0.110 |
Why?
| | Survival Analysis | 2 | 2010 | 1382 | 0.110 |
Why?
| | Mitosis | 1 | 2016 | 199 | 0.110 |
Why?
| | Tumor Suppressor Proteins | 1 | 2017 | 321 | 0.110 |
Why?
| | HeLa Cells | 1 | 2016 | 650 | 0.110 |
Why?
| | Genomics | 3 | 2017 | 833 | 0.110 |
Why?
| | Promoter Regions, Genetic | 3 | 2017 | 1255 | 0.110 |
Why?
| | Cancer Survivors | 1 | 2019 | 326 | 0.110 |
Why?
| | Lymphocyte Activation | 2 | 2002 | 1126 | 0.110 |
Why?
| | STAT3 Transcription Factor | 1 | 2015 | 207 | 0.100 |
Why?
| | Brain | 2 | 2020 | 2930 | 0.100 |
Why?
| | Flow Cytometry | 2 | 2019 | 1172 | 0.100 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 824 | 0.100 |
Why?
| | Retrospective Studies | 6 | 2025 | 17009 | 0.100 |
Why?
| | Phosphorylation | 4 | 2020 | 1732 | 0.100 |
Why?
| | Cell Movement | 2 | 2020 | 965 | 0.100 |
Why?
| | Wnt Proteins | 1 | 2014 | 133 | 0.100 |
Why?
| | Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2012 | 27 | 0.100 |
Why?
| | Cathepsin B | 1 | 2012 | 16 | 0.100 |
Why?
| | Precision Medicine | 1 | 2017 | 456 | 0.100 |
Why?
| | Argonaute Proteins | 1 | 2012 | 31 | 0.090 |
Why?
| | Indoles | 1 | 2017 | 501 | 0.090 |
Why?
| | Acetylcysteine | 1 | 2013 | 138 | 0.090 |
Why?
| | Genomic Structural Variation | 1 | 2012 | 13 | 0.090 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2012 | 140 | 0.090 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 200 | 0.090 |
Why?
| | Luciferases | 1 | 2012 | 152 | 0.090 |
Why?
| | Astrocytoma | 2 | 2025 | 129 | 0.090 |
Why?
| | 3' Untranslated Regions | 1 | 2012 | 152 | 0.090 |
Why?
| | Gene Expression Regulation | 1 | 2021 | 2603 | 0.090 |
Why?
| | Carrier Proteins | 2 | 2012 | 736 | 0.090 |
Why?
| | Colorado | 1 | 2022 | 4562 | 0.090 |
Why?
| | Tubulin | 1 | 2012 | 147 | 0.090 |
Why?
| | Telomerase | 1 | 2013 | 247 | 0.080 |
Why?
| | Carcinogenesis | 2 | 2025 | 229 | 0.080 |
Why?
| | Quality of Life | 2 | 2023 | 3166 | 0.080 |
Why?
| | Acetylation | 1 | 2011 | 252 | 0.080 |
Why?
| | Interleukin-6 | 1 | 2015 | 780 | 0.080 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2012 | 141 | 0.080 |
Why?
| | RNA Interference | 1 | 2012 | 476 | 0.080 |
Why?
| | Acetaminophen | 1 | 2013 | 264 | 0.080 |
Why?
| | Adenosine | 1 | 2012 | 254 | 0.080 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2017 | 682 | 0.080 |
Why?
| | Tyrosine | 2 | 2023 | 221 | 0.080 |
Why?
| | Ki-67 Antigen | 2 | 2022 | 117 | 0.080 |
Why?
| | Hydroxamic Acids | 2 | 2007 | 94 | 0.080 |
Why?
| | Radiosurgery | 1 | 2014 | 400 | 0.080 |
Why?
| | Superoxides | 1 | 2010 | 204 | 0.080 |
Why?
| | Aging | 1 | 2020 | 1964 | 0.080 |
Why?
| | Neoplasm Grading | 2 | 2021 | 307 | 0.080 |
Why?
| | Gene Silencing | 2 | 2007 | 205 | 0.070 |
Why?
| | Disease Models, Animal | 1 | 2019 | 4556 | 0.070 |
Why?
| | T-Lymphocytes | 1 | 1997 | 1982 | 0.070 |
Why?
| | Histone Demethylases | 2 | 2022 | 38 | 0.070 |
Why?
| | Kidney Neoplasms | 1 | 2013 | 412 | 0.070 |
Why?
| | Cluster Analysis | 3 | 2017 | 519 | 0.070 |
Why?
| | Down-Regulation | 1 | 2010 | 627 | 0.070 |
Why?
| | Syndrome | 2 | 2005 | 380 | 0.060 |
Why?
| | Nerve Tissue Proteins | 2 | 2012 | 592 | 0.060 |
Why?
| | Scrotum | 1 | 2006 | 24 | 0.060 |
Why?
| | Exocrine Pancreatic Insufficiency | 1 | 2005 | 23 | 0.060 |
Why?
| | Cyclin-Dependent Kinase 9 | 1 | 2025 | 18 | 0.060 |
Why?
| | Premedication | 1 | 2005 | 42 | 0.060 |
Why?
| | Transplantation Chimera | 1 | 2005 | 56 | 0.060 |
Why?
| | Young Adult | 5 | 2021 | 13990 | 0.060 |
Why?
| | Drug Synergism | 2 | 2017 | 357 | 0.060 |
Why?
| | Anemia, Aplastic | 1 | 2005 | 42 | 0.060 |
Why?
| | CD47 Antigen | 1 | 2025 | 42 | 0.060 |
Why?
| | Molecular Sequence Data | 2 | 2008 | 2929 | 0.060 |
Why?
| | Computer Simulation | 2 | 2021 | 1025 | 0.060 |
Why?
| | RNA | 1 | 2012 | 939 | 0.060 |
Why?
| | Tissue Fixation | 1 | 2025 | 36 | 0.060 |
Why?
| | Testicular Neoplasms | 1 | 2006 | 113 | 0.060 |
Why?
| | Neuroblastoma | 1 | 2006 | 174 | 0.060 |
Why?
| | Paraffin Embedding | 1 | 2025 | 32 | 0.060 |
Why?
| | Neutropenia | 1 | 2005 | 155 | 0.050 |
Why?
| | Formaldehyde | 1 | 2025 | 66 | 0.050 |
Why?
| | Case-Control Studies | 1 | 2012 | 3592 | 0.050 |
Why?
| | Transplantation Conditioning | 1 | 2005 | 186 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2359 | 0.050 |
Why?
| | Prodrugs | 1 | 2024 | 52 | 0.050 |
Why?
| | Chromosomes | 1 | 2024 | 108 | 0.050 |
Why?
| | Graft vs Host Disease | 1 | 2005 | 264 | 0.050 |
Why?
| | Treatment Outcome | 4 | 2024 | 11643 | 0.050 |
Why?
| | Fluorouracil | 1 | 2024 | 235 | 0.050 |
Why?
| | Phenylenediamines | 1 | 2023 | 12 | 0.050 |
Why?
| | Graft Survival | 1 | 2005 | 526 | 0.050 |
Why?
| | Core Binding Factor alpha Subunits | 1 | 2022 | 2 | 0.050 |
Why?
| | Organophosphates | 1 | 2024 | 187 | 0.050 |
Why?
| | Otx Transcription Factors | 1 | 2022 | 15 | 0.050 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2023 | 167 | 0.050 |
Why?
| | Weibel-Palade Bodies | 1 | 2022 | 6 | 0.050 |
Why?
| | fas Receptor | 1 | 2002 | 92 | 0.050 |
Why?
| | Lymphoproliferative Disorders | 1 | 2002 | 57 | 0.040 |
Why?
| | T-Box Domain Proteins | 1 | 2022 | 106 | 0.040 |
Why?
| | Gene Ontology | 1 | 2021 | 53 | 0.040 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2022 | 108 | 0.040 |
Why?
| | Genetic Heterogeneity | 1 | 2021 | 62 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 240 | 0.040 |
Why?
| | Antigens, CD | 3 | 2002 | 555 | 0.040 |
Why?
| | Muscle Proteins | 1 | 2022 | 244 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2023 | 459 | 0.040 |
Why?
| | Ifosfamide | 1 | 2020 | 38 | 0.040 |
Why?
| | Transcription Factor HES-1 | 1 | 2019 | 5 | 0.040 |
Why?
| | Smoothened Receptor | 1 | 2019 | 5 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2019 | 5389 | 0.040 |
Why?
| | MyoD Protein | 1 | 2019 | 31 | 0.040 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 279 | 0.040 |
Why?
| | Gain of Function Mutation | 1 | 2019 | 36 | 0.040 |
Why?
| | Cyclophosphamide | 1 | 2020 | 266 | 0.040 |
Why?
| | Apoptosis Regulatory Proteins | 2 | 1997 | 186 | 0.040 |
Why?
| | RNA Splice Sites | 1 | 2019 | 50 | 0.040 |
Why?
| | Risk Factors | 3 | 2021 | 10699 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 369 | 0.040 |
Why?
| | Aminopyridines | 1 | 2019 | 127 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2002 | 668 | 0.040 |
Why?
| | Gene Regulatory Networks | 1 | 2021 | 318 | 0.030 |
Why?
| | Adult | 5 | 2021 | 40262 | 0.030 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 1997 | 264 | 0.030 |
Why?
| | Autoimmune Diseases | 1 | 2002 | 463 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 610 | 0.030 |
Why?
| | RNA Splicing | 1 | 2019 | 284 | 0.030 |
Why?
| | Drug Approval | 1 | 2018 | 89 | 0.030 |
Why?
| | Receptors, HIV | 1 | 2017 | 23 | 0.030 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2017 | 63 | 0.030 |
Why?
| | Mucin-1 | 1 | 2017 | 22 | 0.030 |
Why?
| | Cytogenetic Analysis | 1 | 2017 | 33 | 0.030 |
Why?
| | Alternative Splicing | 1 | 2019 | 247 | 0.030 |
Why?
| | Transfection | 1 | 2019 | 938 | 0.030 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 1997 | 153 | 0.030 |
Why?
| | DNA, Complementary | 1 | 1997 | 276 | 0.030 |
Why?
| | Jurkat Cells | 1 | 1997 | 114 | 0.030 |
Why?
| | Homeodomain Proteins | 1 | 2021 | 523 | 0.030 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 139 | 0.030 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2017 | 123 | 0.030 |
Why?
| | Global Health | 1 | 2019 | 394 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2017 | 321 | 0.030 |
Why?
| | Radiotherapy | 1 | 2017 | 206 | 0.030 |
Why?
| | Genetic Variation | 1 | 2021 | 982 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2017 | 382 | 0.030 |
Why?
| | Cell Culture Techniques | 1 | 2017 | 375 | 0.030 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2015 | 87 | 0.030 |
Why?
| | Canada | 1 | 2016 | 428 | 0.030 |
Why?
| | Zinc Finger Protein Gli2 | 1 | 2014 | 4 | 0.030 |
Why?
| | Cytogenetics | 1 | 2014 | 11 | 0.030 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 2014 | 21 | 0.030 |
Why?
| | Health Status | 1 | 2019 | 833 | 0.030 |
Why?
| | Tissue Array Analysis | 1 | 2014 | 50 | 0.030 |
Why?
| | Hematopoietic Stem Cells | 1 | 1997 | 420 | 0.030 |
Why?
| | Myeloid Cells | 1 | 2015 | 148 | 0.030 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2014 | 58 | 0.030 |
Why?
| | Gene Expression | 2 | 2010 | 1487 | 0.020 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2014 | 78 | 0.020 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2013 | 75 | 0.020 |
Why?
| | Imaging, Three-Dimensional | 1 | 2017 | 582 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2017 | 1715 | 0.020 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2013 | 194 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2013 | 405 | 0.020 |
Why?
| | Gene Duplication | 1 | 2012 | 67 | 0.020 |
Why?
| | Monocytes | 1 | 2015 | 538 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2015 | 508 | 0.020 |
Why?
| | Middle Aged | 3 | 2021 | 35762 | 0.020 |
Why?
| | Methylation | 1 | 2012 | 242 | 0.020 |
Why?
| | Translocation, Genetic | 1 | 2012 | 115 | 0.020 |
Why?
| | B-Lymphocytes | 1 | 1997 | 876 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 2 | 2016 | 3857 | 0.020 |
Why?
| | Glutathione | 1 | 2013 | 375 | 0.020 |
Why?
| | Inflammation | 1 | 2023 | 2877 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1322 | 0.020 |
Why?
| | Genome | 1 | 2012 | 306 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 5988 | 0.020 |
Why?
| | Age Factors | 1 | 2017 | 3313 | 0.020 |
Why?
| | Transforming Growth Factor beta | 1 | 2012 | 479 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1833 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2014 | 2111 | 0.020 |
Why?
| | Disease Progression | 1 | 2016 | 2840 | 0.020 |
Why?
| | Cytokines | 1 | 2015 | 2061 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 6021 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2014 | 3403 | 0.010 |
Why?
| | Azacitidine | 1 | 2006 | 156 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2012 | 2143 | 0.010 |
Why?
| | Risk Assessment | 1 | 2014 | 3637 | 0.010 |
Why?
| | Receptors, Interleukin-2 | 1 | 2002 | 64 | 0.010 |
Why?
| | Lectins, C-Type | 1 | 2002 | 62 | 0.010 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 2002 | 100 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2012 | 2730 | 0.010 |
Why?
| | Cytoplasm | 1 | 2002 | 269 | 0.010 |
Why?
| | Interleukin-4 | 1 | 2002 | 206 | 0.010 |
Why?
| | Interleukin-2 | 1 | 2002 | 437 | 0.010 |
Why?
| | T-Lymphocyte Subsets | 1 | 2002 | 415 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2011 | 6424 | 0.010 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2002 | 388 | 0.010 |
Why?
| | Interferon-gamma | 1 | 2002 | 784 | 0.010 |
Why?
| | Restriction Mapping | 1 | 1997 | 80 | 0.010 |
Why?
| | Chromosomes, Human, Pair 2 | 1 | 1997 | 28 | 0.010 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 1997 | 157 | 0.010 |
Why?
| | Interleukin-7 | 1 | 1997 | 65 | 0.010 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 1997 | 96 | 0.010 |
Why?
| | Genes | 1 | 1997 | 226 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 1997 | 396 | 0.010 |
Why?
| | Calcium | 1 | 2002 | 1182 | 0.010 |
Why?
| | Bone Marrow | 1 | 1997 | 304 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 1997 | 1253 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1997 | 2154 | 0.010 |
Why?
| | Cells, Cultured | 1 | 1997 | 4146 | 0.000 |
Why?
|
|
Vibhakar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|